Pancragen

Bioregulator / Metabolic / blood sugar

Supports pancreas functional activity and adaptive restoration

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Peptide bioregulator
Primary mechanism: Synthetic short-chain Khavinson/Cytogen peptide; gene-expression/protein synthesis signaling
Primary market use: Bioregulator / Metabolic / blood sugar
Bioregulator family: Synthetic Cytogen
Tissue / organ target: Pancreas
Sequence: Ala-Glu-Asp-Gly

Pharmacology

Oral bioavailability: Route-dependent / verify
Half-life: Plasma t1/2 class estimate ~0.5–2 h; aftereffect 1.5–2 months
Route tags: SubQ; IM
Evidence level: Bioregulator guide / practitioner-market protocol signal
Clinical status: Supplement/research bioregulator; jurisdiction-dependent
Value-for-money score: 8 / 10
Durability / after-effect: Aftereffect/durability window: 1.5–2 months reported for Cytogen injectable cycles.

Reported protocol signal

Common reported Cytogen injectable protocol: 1–10 mg daily for 10–20 days SQ/IM; popular simplified protocol 2 mg daily for 20–30 days, 1 month on / 2 months off, 2–3×/year.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Stackability

Connect to Bioregulator_Map and Protocol_Templates sheets; do not treat stacks as standalone compounds.

Notes

Bioregulator/Cytogen/Cytomax mapping from supplemental files